Treatment Set TS331634 (Antigen Laboratories, Inc.)


Welcome to the PulseAid listing for the Treatment Set TS331634 drug offered from Antigen Laboratories, Inc.. This Standardized Insect Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Antigens, Dermatophagoides [Chemical/Ingredient],Insect Proteins [Chemical/Ingredient],Allergens [Chemical/Ingredient],Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [Chemical/Ingredient],Allergens [Chemical/Ingredient] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Antigen Laboratories, Inc.
NON-PROPRIETARY NAME: Treatment Set TS331634
SUBSTANCE NAME: DERMATOPHAGOIDES FARINAE; CYNODON DACTYLON POLLEN; ALTERNARIA ALTERNATA; SORGHUM HALEPENSE POLLEN; IVA ANNUA VAR. ANNUA POLLEN; COCHLIOBOLUS SATIVUS; PHOMA DESTRUCTIVA; PLEOSPORA HERBARUM
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Standardized Insect Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Antigens, Dermatophagoides [Chemical/Ingredient],Insect Proteins [Chemical/Ingredient],Allergens [Chemical/Ingredient],Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [Chemical/Ingredient],Allergens [Chemical/Ingredient]
ROUTE: INTRADERMAL; SUBCUTANEOUS
DOSAGE FORM: INJECTION, SOLUTION
MARKETING CATEGORY NAME: BLA
START MARKETING DATE: 1986-10-31
END MARKETING DATE: 0000-00-00


Treatment Set TS331634 HUMAN PRESCRIPTION DRUG Details:

Item DescriptionTreatment Set TS331634 from Antigen Laboratories, Inc.
LABELER NAME: Antigen Laboratories, Inc.
DEA SCHEDULE:
ACTIVE STRENGTH: 2000; 80; .0004; .01; .01; .002; .002; .002([AU]/mL; [BAU]/mL; g/mL; g/mL; g/mL; g/mL; g/mL; g/mL)
START MARKETING DATE: 1986-10-31
END MARKETING DATE: 0000-00-00
PRODUCT ID: 49288-0720_b29faef0-2249-45b7-974b-212faa8c91d8
PRODUCT NDC: 49288-0720
APPLICATION NUMBER: BLA102223

Other DERMATOPHAGOIDES FARINAE; CYNODON DACTYLON POLLEN; ALTERNARIA ALTERNATA; SORGHUM HALEPENSE POLLEN; IVA ANNUA VAR. ANNUA POLLEN; COCHLIOBOLUS SATIVUS; PHOMA DESTRUCTIVA; PLEOSPORA HERBARUM Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Antigen Laboratories, Inc.Treatment Set TS331634